The DPP-4 inhibitor vildagliptin: Robust glycaemic control in type 2 diabetes and beyond

Diabetes, Obesity and Metabolism

Volumn 9, Issue SUPPL.1, 2007, Pages 32-39

  Panina, Gaia ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Combination therapy; Dipeptidyl peptidase 4; Prediabetes; Type 2 diabetes mellitus; Vildagliptin; cell function

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIMEPIRIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; VILDAGLIPTIN;

ABDOMINAL PAIN; ADD ON THERAPY; AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CELL FUNCTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; EDEMA; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PERIPHERAL EDEMA; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 34548763078     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00763.x     Document Type: Review

References (19)

1. Ahren B, Landin-Olsson M, Jansson P et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084.
2. Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894.
3. Villhauer EB, Brinkman JA, Naderi GB et al. 1- (3-hydroxy-1-damantly)ami no]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46: 2774-2789.
4. Balas B, Baig MR, Watson C et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007; 92: 1249-1255.
5. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 2007 (Epub ahead of print).
6. Rosenstock J, Baron MA, Dejager S et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. Diabetes Care 2007; 30: 217-223.
7. Ahrén B, Gomis R, Standl E et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF 237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874-2880.
8. Bosi E, Camisasca RP, Collober C et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-895.
9. Garber AJ, Camisasca RP, Jauffret S, Baron MA. Efficacy and tolerability of vildagliptin added to a sulfonylurea (SU) in patients with type 2 diabetes (T2DM). Diabetes 2007; 56 (Suppl. 1): A134. Abstract 501-P.
10. Fonseca V, Schweizer A, Albrecht D et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148-1155.
11. Rosenstock J, Rendell MS, Landin-Olsson M et al. Effects of vildagliptin in subjects with IGT. Diabetes 2007; 56 (Suppl. 1): A135. Abstract 505-P.
12. He Y-L, Wang Y, Bullock JM et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007; 47: 633-641.
13. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 132-138. doi: 10.1016/ j.diabres.2006.12.009
14. Dejager S et al. Presented at ADA Annual Meeting; June 9-13, 2006; Washington, DC. Abstract 120-OR.
15. Scherbaum WA, Schweizer A, Mari A et al. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes (T2DM) and mild hyperglycemia. Diabetes 2007; 56 (Suppl. 1): A134. Abstract 503-P.
16. Nathwani A. The use of vildagliptin for treatment of patients with type 2 diabetes mellitus. Presented at American Diabetes Association - 66th Scientific Sessions, Washington, DC, 13 June 2006.
17. Ahrén B, Pacini G, Foley J et al. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-1940.
18. Garber AJ, Schweizer A, Baron MA et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9: 166-174.
19. Rosenstock J, Baron MA, Camisasca R-P et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 175-185.